Acute type B aortic dissection is a challenging acute aortic syndrome in which thoracic endovascular aortic repair (TEVAR) is indicated for such complications as rupture and malperfusion. 1,2 The role of TEVAR in this setting remains controversial when classic complications are absent. [1][2][3][4] The adverse natural history of uncomplicated acute type B dissection has recently prompted selective consideration of TEVAR to supplement best medical therapy. 3,4 The report by Hong and colleagues 5 in this issue of the Journal evaluates the rationale for TEVAR in uncomplicated type B aortic dissection. The authors highlight the advances in classification, emergence of high-risk features, and current management options and also suggest extended indications for TEVAR based on the presence of high-risk features. 5,6 How might their report stratify our management approach to type B aortic dissection? First, uncomplicated presentations are now defined by an absence of high-risk features, malperfusion, or rupture. [5][6][7] These patients require intense medical therapy, including titrated analgesia, strict blood pressure control, and close monitoring for disease progression. 5,6 This medical management can often be successful through the hyperacute (the first 24 hours of symptoms), acute (1-14 days from symptom onset), and subacute (15-90 days from symptom onset) phases of care. If a systolic blood pressure